久久综合日本久久综合,亚洲成AV人片在线观看天堂无码,国产在线视频不卡一区二区,久久久久看免费高清特色大片

武漢佰樂博生物技術(shù)有限公司
   
     
您當(dāng)前的位置: 網(wǎng)站首頁 > 產(chǎn)品展廳 >試劑盒 >BioSim Carlumab ELISA Kit(KDC97801)
BioSim Carlumab ELISA Kit(KDC97801)
  • 品牌:AntibodySystem
  • 產(chǎn)地:France
  • 型號:96 assays
  • 貨號:KDC97801
  • 發(fā)布日期: 2022-07-25
  • 更新日期: 2024-10-23
產(chǎn)品詳請
產(chǎn)地 France
保存條件 2-8 ℃
品牌 AntibodySystem
貨號 KDC97801
用途 For Research Use Only.
檢測方法 Elisa
CAS編號
保質(zhì)期 1 year
適應(yīng)物種 Carlumab
檢測限 0.156 ug /ml
數(shù)量 99999
包裝規(guī)格 96 assays
標(biāo)記物 Unconjugate
純度 95%%
樣本 Plasma, Serum
應(yīng)用 Elisa
是否進(jìn)口


Catalog No.

KDC97801

Stability and Storage

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Detection method

Colorimetric

Precision

CV<20%

Sample type

Plasma, Serum

Assay type

Quantitative

Sensitivity

0.156 μg/ml

Range

0.31-5 μg/mL

Recovery

80-120%

Specifications

Carlumab

Alternative Names

CNTO 888, CAS: 915404-94-3

Background

Carlumab, developed by Janssen Biotech, is a recombinant human IgG1 monoclonal antibody targeting CC chemokine ligand 2 (CCL2). The recombinant protein has been developed for the treatment of cancer and prostate cancer, and has also been studied in systemic sclerosis, atherosclerosis, diabetic nephropathy, liver fibrosis, and type 2 diabetes. In the beginning, phage display technology was used to confirm the high affinity between Carlumab and CCL2, which provided a basis for future clinical trials. In 2013, Carlumab was used to treat metastatic castrated prostate cancer and solid tumors. The anti-tumor activity of Carlumab was preliminarily determined through the study of its safety, tolerance, pharmacokinetics-pharmacodynamics and anti-tumor activity. Subsequently, some studies have evaluated the safety and efficacy of Carlumab in the treatment of (IPF) with idiopathic pulmonary fibrosis, but the results are not satisfactory. Due to the limited success rate of clinical trials, carlumab was discontinued in 2012.

Shipping

2-8 ℃

Note

For Research Use Only.


Aiming to develop the most reliable bioreagents, AntibodySystem SAS was founded in 2019 in France by a team of professionals from top industrial companies and research institutes. The collective scientific and technical experiences in our team have brought breaking throughs in multiple product developments, including recombinant antibodies, recombinant proteins, biosimilar, RUO ELISA kits and other related products. By working with talented researchers and technicians, AntibodySystem continues to upgrade product qualities and lower the overall cost, offering accountable and affordable solutions for biolabs all over the world. Since its establishment, AntibodySystem has built long term and stable collaborations with academia, pharmaceutical industry, biotech companies and research hospitals, supporting their R&D by AntibodySystem's bioreagents with excellent data accuracy and reproducibility.




AntibodySystem由具有30多年蛋白抗體開發(fā)經(jīng)驗的 創(chuàng)立于法國,專注于生命科學(xué)和生物制藥領(lǐng)域研究,總部位于法國斯特拉斯堡市。AntibodySystem自主開發(fā)了高效、高產(chǎn)的真核重組表達(dá)系統(tǒng),利用該系統(tǒng)生產(chǎn)了高質(zhì)量的重組蛋白、抗體產(chǎn)品。目前產(chǎn)品包括藥物靶點蛋白以及對照抗體藥物、Invivo功能性抗體、SAA系列流式抗體、PEG抗體、磷酸化抗體、抗小分子抗體、ADA抗體、PK&ADA ELISA試劑盒。


普健生物作為AntibodySystem在亞洲區(qū)授權(quán) ,致力于為廣大科研工作者提供 的產(chǎn)品服務(wù)。

如果您對我們的產(chǎn)品感興趣,請聯(lián)系027-65279366。

以上產(chǎn)品僅用于科研,產(chǎn)品信息以產(chǎn)品 為準(zhǔn)






聯(lián)系方式
手機:18162686757
微信掃一掃
南京市| 崇礼县| 乌兰察布市| 淳化县| 清苑县| 无锡市| 安宁市| 张家港市| 大姚县| 丰县| 惠东县| 灌阳县| 肇东市| 隆昌县| 大方县| 山阳县| 河东区| 保山市| 兰考县| 安顺市| 吴江市| 留坝县| 建平县| 蕲春县| 麦盖提县| 嵊州市| 和龙市| 恭城| 万荣县| 邻水| 大邑县| 阿勒泰市| 江阴市| 大化| 松滋市| 明光市| 黑龙江省| 合作市| 秦皇岛市| 电白县| 西华县|